Insta
Big Win In India's Fight Against Covid-19: Covishield Vaccine Gets Conditional Approval
SII's Covishield vaccine (Pic Via Twitter)
The 10-member Subject Expert Committee (SEC) of India's Central Drug Standard Control Organisation (CDSCO) today (1 January) approved emergency use authorisation of the Oxford-AstraZeneca coronavirus vaccine 'Covishield'.
As per reports the SEC recommended in favour of the emergency use authorisation to the DCGI subject to certain conditions. The vaccine has been developed by scientists at the UK's Oxford University and is produced by AstraZeneca.
The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech for its Covaxin.
Once the vaccines are cleared by the committee, the application will be sent to Drugs Controller General of India (DCGI) V G Somani for final approval.
The vaccine doses may start getting transported to states from tomorrow.
The Serum Institute of India which locally manufactures the vaccine has rolled out 50 million doses of Covishield - majority of which will be used in India.
The overall efficacy of this vaccine is pegged at 70.4 per cent and can be stored in domestic refrigeration. It is likely to be priced well below Rs 1,000 for the two mandatory doses.
As per reports, similar approval may also be given to the second vaccine which has been jointly developed by Indian Council of Medical Research (ICMR) and Bharat Biotech.
With Inputs From IANS
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
